(Q38009746)

English

Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

based on heuristic

inferred from title

acute coronary syndrome

1 reference

based on heuristic

inferred from title

author name string

Shahdad Azmoon

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Dominick J Angiolillo

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

9 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Catheterization and Cardiovascular Interventions

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

81

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

232-242

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Basic principles of platelet biology and clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Update on the clinical development of cangrelor.

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Platelet inhibition with cangrelor in patients undergoing PCI.

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Intravenous platelet blockade with cangrelor during PCI.

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Elinogrel: pharmacological principles, preclinical and early phase clinical testing

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Clopidogrel-drug interactions

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCCD.24480

21 January 2018

Identifiers

10.1002/CCD.24480

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38009746&oldid=1737222133"